2019 Scientific Sessions

Expanding Applications for Intravenous Platelet Inhibition

The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome (ACS). Through case presentations, find out about optimal anti-platelet coverage in patients with ACS and complex stable CAD and the pharmacotherapy treatments. Gain valuable insight into the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Plus, learn vital tips from experts in the field to help you with the transition to oral P2Y12 receptor blockades.
Case #1 (With Discussion): Intravenous Platelet Inhibition During PCI in ACS
Deepak L. Bhatt, M.D., M.P.H., MSCAI, Brigham And Women's Hospital, Newton, MA
Case #3 (With Discussion): Intravenous Platelet Inhibition for Bridging
Eric A. Osborn, M.D., Ph.D., FSCAI, Beth Israel Deaconess Medical Center, Boston, MA
See more of: Satellite Sessions